Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Therapeutic Approach for CLL Biomarkers: Low-Risk Should Be Treated w/ anti-CD20+Chlorambucil, High-Risk w/ BCRis, Venetoclax, or Combos

227 views
December 20, 2019
Comments 0
Login to view comments. Click here to Login